Texas Ruling

Institute of Reproductive Grief Care

Response to Media Coverage Related to the

Texas Ruling 2:22-CV-223-Z

On April 7, 2023, a federal judge in Texas issued a ruling on the medication abortion drug mifepristone, suspending the U.S. Food and Drug Administration’s approval of it.

Within his judgment was a reference to a study that was created in coordination with the Institute of Reproductive Grief Care, related to anonymous posts on our site abortionchangesyou.com. This inclusion has driven national interest in our three-year old study.

Our full response to this interest is here.

We would like to thank the national press, and especially The Washington Post for their willingness to present our viewpoint, which does not support any predefined positions.

This Letter to the Editor reflects the opinions of the Institute of Reproductive Grief Care and does not reflect the opinions or thoughts of the researchers who created the study, nor their organizations or affiliations.